Of the 11 nonresponder patients with breast cancer, seven received everolimus on the basis of a PIK3CA mutation (3× His1047Arg, 2× Glu545Lys, and 2× Glu542Lys) and four received everolimus on the basis of PTEN inactivation. This evidence concerns the gene PIK3CA and breast carcinoma.